Jesse Cabiling
Adult Health · Hasbrouck Heights, NJNPI 1790443521
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.2% of the total across 71 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by Novartis at 24.1% of the total. 2025 is the largest year on record at $609, 2.8 times the $220 reported in 2022.
Across 71 payments — averaging $24.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$419
- Rigel Pharmaceuticals, Inc.$224
- AstraZeneca$154
- Seagen Inc.$100
- Daiichi Sankyo Inc.$91
- Sanofi$87
- plus $662 from 16 others
What the payments were for
- Food & beverage$1,63894%
- Education$1006%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 18 | $419 |
| Rigel Pharmaceuticals, Inc. | 9 | $224 |
| AstraZeneca | 7 | $154 |
| Seagen Inc. | 1 | $100 |
| Daiichi Sankyo Inc. | 4 | $91 |
| Sanofi | 4 | $87 |
| Amgen | 4 | $78 |
| Sobi, Inc | 2 | $74 |
| Merck | 3 | $71 |
| Tersera Therapeutics LLC | 2 | $65 |
| Jazz Pharmaceuticals Inc. | 2 | $55 |
| Shield Therapeutics Inc | 3 | $49 |
| Stemline Therapeutics Inc. | 2 | $46 |
| Bristol Myers Squibb | 2 | $44 |
| Ipsen Biopharmaceuticals, Inc | 1 | $26 |
| Eisai Inc. | 1 | $24 |
| Johnson & Johnson | 1 | $24 |
| Melinta Therapeutics, LLC | 1 | $24 |
| Astellas Pharma US Inc | 1 | $24 |
| Syndax Pharmaceuticals, Inc. | 1 | $21 |
| Immunocore Limited | 1 | $19 |
| Bayer | 1 | $18 |
How this compares
$1,738 in reported general payments places this provider in the 80th percentile of 1,135 adult health providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 21 | $13,476 |
| XareltoRivaroxaban | 14 | $9,724 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $24 | $9,72414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,135 adult health providers in New Jersey.
Other adult health in Hasbrouck Heights
- June HalperHackensack$358K
- Kara SaggiomoCamden$127K
- Entela AhmetiPomona$75K
- Phyllis McKiernanHackensack$72K
- Denise ForceMiddletown$71K
- Kathleen SenecaHillsborough$64K
- Diane AndresenNorthvale$60K
- Dana BeenstockFreehold$51K
- Phyllis DudaCamden$46K
- Anthony WalkoWestwood$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.